Meeting
2022 ASCO Annual Meeting
Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).
Authors
Amita Patnaik
START San Antonio, San Antonio, TX
Amita Patnaik , Justin A Call , Anna Spreafico , Lisle Nabell , Mingjin Yan , Andres Forero-Torres , Maura L. Gillison
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT05208762
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3154)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3154
Abstract #
TPS3154
Poster Bd #
144b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+t CELLS in patients with advanced solid tumors.
First Author: Jiajian Liu
Poster
2020 ASCO Virtual Scientific Program
A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.
First Author: Jermaine Coward
First Author: Daniel Wilhelm Mueller
Poster
2019 ASCO Annual Meeting
Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.
First Author: Jermaine Coward